Glaukos Reports 25 Percent Net Sales Increase in 2025 First Quarter, Reaffirms Full-Year Guidance

ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, has announced financial results for the first quarter ended March 31, 2025. Net sales of $106.7 million in the first quarter of 2025 increased 25 percent on a reported basis, or 26 percent on a constant currency basis, compared with $85.6 million in the same period in 2024, the company advised. The company also reported glaucoma record net sales of $88.1 million in the first quarter of 2025, a 31 percent increase year-over-year. U.S. glaucoma record net sales of $59.1 million in the first quarter of 2025 increased 41 percent year-over-year.